Michelle Hickey PhD

Michelle Hickey

Academic Title
Assistant Director, Immunogenetics
Assissant Professor, Pathology and Lab
Professor, Pathology & Laboratory Medicine

 

Bio
Dr. Hickey is Assistant Director of the UCLA Immunogenetics Center and an Assistant Professor with the Department of Pathology and Laboratory Medicine. Dr. Hickey earned her PhD in 2006 from the University of California, Irvine after studying chemokine and chemokine receptor involvement in immune cell trafficking to the central nervous system in a murine model of innate and adaptive immunity. She then completed her postdoctoral work in 2012 at UCLA in the area of adoptive cellular allogeneic immunotherapy for patients with primary malignant brain tumors. This was followed by three years of training in Immunogenetics and Histocompatibility at the UCLA Immunogenetics Center. Dr. Hickey is a Diplomat of the American Board of Histocompatibility of Immunogenetics. Her current research is in understanding the effects of donor specific HLA and non-HLA antibodies on allograft pathology and outcomes after organ transplant.

Selected Publications
Hickey MJ, Valenzuela NM, Reed EF. Alloantibody Genertion and Effector Function Following Sensitization to Human Leukocyte Antigen. Review Article. Frontiers In Immunology. 2016 (In Press).

Zhang JQ, Hickey MJ, Valenzuela NM, Zhang X, Lan JH, Cecka M, Reed EF. Histocompatibility and Immunogenetics for Solid Organ Transplantation. In: Atlas of Solid Organ Transplant Pathology. Wallace WD, Naini BV, editors. London: Springer Science+Business Media; 2015 (In press).

Wozniak LJ, Hickey MJ, Venick RS, Vargas JH, Farmer DG, Busuttil RW, McDiarmid SV, Reed EF. Donor-Specific HLA Antibodies are Associated with Late Allograft Dysfunction After Pediatric Liver Transplantation. Transplantation. 2015. 99:1496-1422.

Erickson KL, Hickey MJ, Kato Y, Malone CC, Owens GC, Prins RM, Liau LM, Kasahara N, Kruse CA. Radial Mobility and Cytotoxic Function of Retroviral Replicating Vector Transduced, Non-adherent Alloresponsive T Lymphocytes. J Vis Exp. 2014. 96:e52416.

Hickey MJ, Kasahara N, Mueller BM, Kruse CA. Combining cellular and gene therapy approaches for treatment of intracranial tumors. Authors View. Oncoimmunol. 2013. 2:e25989.

Hickey MJ, Malone CC, Erickson KL, Lin A, Soto H, Ha ET, Kamijima S, Inagaki A, Takahashi M, Kato Y, Kasahara N, Mueller B, Kruse CA. Combined Alloreactive CTL Cellular Therapy with Prodrug Activator Gene Therapy in a Model of Breast Cancer Metastatic to the Brain. Clin Cancer Res. 2013.19:4137-4148.

Hickey MJ, Malone CC, Erickson KE, Gomez GG, Young EL, Liau LM, Prins RM, Kruse CA. Implementing Preclinical Study Findings to Protocol Design: Translational Studies with Alloreactive CTL for Gliomas. Am J Transl Res. 2012. 4:114-123.

Hickey MJ, Malone CM, Erickson KE, Jadus MR, Prins RM, Liau LM, Kruse CA. Cellular and Vaccine Therapeutic Approaches for Glioma. J Immunother. 2010, 8:100-110.

Hickey MJ, Held K, Baum E, Gao J, Murphy PM, and Lane TE. CCR1 deficiency increases susceptibility to fatal coronavirus infection of the central nervous system. Viral Immunol., 2007, 20(4)599-608.

Glass WG, Hickey MJ, Hardison JL, Liu MT, Manning JE, Lane TE. Antibody targeting of the CC chemokine ligand 5 (CCL5) results in diminished leukocyte infiltration into the central nervous system and reduced neurologic disease in a viral model of multiple sclerosis. J Immunol. 2004, 172:4018-4025.